Cross-validation of a high-performance liquid chromatography nevirapine plasma assay in a resource-limited setting in Zimbabwe

An international HIV pharmacology specialty laboratory (PSL) was established at the University of Zimbabwe to increase bioanalytical and investigator capacities. Quantitation of plasma nevirapine in samples from the AIDS Clinical Trials Group protocol 5279 was compared between the University of Nebraska Medical Center PSL and the University of Zimbabwe PSL. Both PSLs employed internally developed methods utilising reverse-phase high-performance liquid chromatography with ultraviolet detection. Eighty-seven percent of the cross-validation results exhibited ± 20% difference.

**Keywords:** cross-validation; HIV; root-cause analysis; high-performance liquid chromatography.

**Introduction**

The University of Zimbabwe (UZ) International HIV pharmacology specialty laboratory (IPSL) was established to increase HIV pharmacology-related research and support research investigator capacity in Africa.¹ The UZ-IPSL performs drug development assay and clinical research specimens analyses, specifically drug-drug interactions, pharmacokinetic and pharmacodynamic data analyses.

The Clinical Pharmacology Quality Assurance programme, which monitors all PSLs within the AIDS Clinical Trials Group, provided technical guidance to and developed a comparative nevirapine validation study for the UZ-IPSL to analyse replicate HIV clinical samples. Validation of the nevirapine bioanalytics method² was essential at the time because of nevirapine use in the sub-Saharan region and results were generated by a reverse-phase high-performance liquid chromatography (HPLC) system using ultraviolet detection with gradient-elution separation.³⁴⁵ This report compares nevirapine bioanalysis at two laboratories: the United States-based, University of Nebraska Medical Center Pharmacology Specialty Laboratory (UNMC-PSL) and the UZ-IPSL. The UNMC-PSL served as the AIDS Clinical Trials Group 5279 (A5279) protocol designated laboratory. The UNMC-PSL, during the time of the A5279 study, participated in the Clinical Pharmacology Quality Assurance proficiency testing (PT) programme to assure nevirapine assay performance and accuracy. Although each PSL validated the nevirapine assay separately, the lack of data comparing the bioanalytical capacity of pharmacology laboratories in low-middle income countries using clinical samples (rather than spiked plasma samples) was the justification for this project.

Therefore, implementation of the project was the last stage in determining UZ-IPSL’s readiness to begin assaying human samples for clinical trials.

**Methods**

**Ethical considerations**

Data files used in this comparison study were de-identified and Clinical Pharmacology Quality Assurance was blinded to any data associated with samples. This article followed all ethical standards for research without direct contact with human or animal subjects.

**How to cite this article:** Makita-Chingombe F, Podany AT, Mykris T, et al. Cross-validation of a high-performance liquid chromatography nevirapine plasma assay in a resource-limited setting in Zimbabwe. Afr J Lab Med. 2021;10(1), a1264. https://doi.org/10.4102/ajlm.v10i1.1264

**Copyright:** © 2021. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
Project design
The UZ-IPSL utilised the A5279 replicate samples \((n = 95)\) that were available at the UZ College of Health Sciences Clinical Trial Research Center (UZCHS-CTRC) for cross-validation of nevirapine assays between the UNMC-PSL and the UZ-IPSL. A5279 was a multi-centre, phase III clinical trial investigating the use of short-course rifapentine or isoniazid for the prevention of active tuberculosis in HIV-positive adults. In A5279, nevirapine pharmacokinetics when co-administered with rifapentine and isoniazid was one of the exploratory objectives. All A5279 primary aliquots collected from the UZ AIDS Clinical Trials Group CTRC were analysed for nevirapine by the protocol designated PSL at the UNMC-PSL.

A5279 sample collection and processing
Plasma samples for the quantitation of nevirapine concentrations were obtained from A5279 study participants. Blood was collected into potassium ethylenediaminetetraacetic acid collection tubes and transported on ice to the processing laboratory within 1 h where the plasma was separated from cells by centrifugation \((1200 \times g, 10 \text{ min}, 4 \degree C)\). The plasma aliquots were frozen \((-70 \degree C)\) and shipped to the UNMC-PSL. The UZCHS-CTRC retained secondary aliquots for the UZ-IPSL cross-validation assay.

University of Nebraska Medical Center PSL nevirapine assay
A5279 primary plasma aliquots were shipped from UZCHS-CTRC on dry ice to the UNMC-PSL for determination of the nevirapine. The UNMC-PSL nevirapine determination assay had a quantitation range of 25 ng/mL to 10 000 ng/mL. Samples measuring above the quantitation range were diluted and reanalysed using a validated dilution protocol. Solid-phase extraction was utilised to prepare samples for analysis. The UNMC-PSL utilised a Waters e2695 HPLC coupled to a Waters 2489 ultraviolet (Waters, Milford, Massachusetts, United States) detector, which was controlled with Empower 2 (Waters, Milford, Massachusetts, United States) software as the analytical platform. The performance of the assay was compliant with the United States Food and Drug Administration bioanalytical guidelines. Peak purity for nevirapine was assessed to confirm the absence of interferences from potential impurities also extracted from the patient’s sample. A5279 samples were assayed over five runs; the two last runs included samples that were above the upper limit of quantification and were diluted \((1:8)\) according to the validated dilution protocol.

Data management and analysis
The UZ-IPSL nevirapine results were submitted to the AIDS Clinical Trials Group Data Management Center portal using the Data Submission Utility (Frontier Science Foundation Inc., Brookline, Massachusetts, United States). The A5279 study team approved the release of the UNMC A5279 nevirapine concentration results for comparison with the UZ-IPSL results. The original nevirapine concentration data from the UNMC-PSL were used in the specified A5279 protocol pharmacokinetics analysis; no UNMC-PSL derived pharmacokinetics data were used in the per-protocol study analysis. The Data Management Center compiled the data and provided the de-identified data files to the Clinical Pharmacology Quality Assurance PT unit to perform blinded, comparative statistical analyses of the nevirapine results. After examination (Omnibus 2) and finalisation of the data, the analyses of the paired \(t\)-test, Deming regression and Bland-Altman analyses were completed using Prism GraphPad (version 8.3; San Diego, California, United States) software.

Results
Ninety-five replicate plasma aliquots were bioanalysed. The nevirapine concentration range in the analysed samples was \((-2000 \text{ ng/mL} \sim 34000 \text{ ng/mL} (-17\text{-fold})\). Of this, 97\% (\(n = 92\)) ranged between 2000 ng/mL and 20 000 ng/mL and the remaining 3\% (\(n = 3\)) were above 20 000 ng/mL and not contiguous (Table 1, Figure 1a). The nevirapine concentration values from the laboratories were tested for normality and only data \(≤ 15 000 \text{ ng/mL}\) or less were normally distributed. Data 15 000 ng/mL reflected the upper limit of the UZ-IPSL assay and was appropriate because it more closely represented the previously reported nevirapine steady state concentrations \((5086 \text{ ng/mL} \sim 13368 \text{ ng/mL} \sim 19.1 \text{ uM to} \sim 50.2 \text{ uM})\). Of the data, 93\% (\(n = 88\)) were 15 000 ng/mL or less (Table 1) while 7\% (\(n = 7\)) were above this value. Therefore, the seven sample pairs were excluded from the method comparison. After exclusion, an additional sample pair was identified as a significant outlier using the Grubbs test and was also excluded.

The two-tailed paired \(t\)-test of the final data set \((n = 87)\) (Table 1) showed UZ-IPSL nevirapine values were significantly higher with a constant error of 3\% – 4\% more than UNMC-PSL values. The Deming regression analysis (Figure 1b) and the Bland-Altman plots (Figure 2) further confirmed the higher values from the UZ-IPSL. As shown in Figure 2a, regression analysis using the difference plot indicated an
**TABLE 1:** A comparative study of nevirapine assay results conducted at the University of Zimbabwe International HIV Pharmacology Specialty Laboratory (Harare, Zimbabwe, May 2018) and the University of Nebraska Medical Center Pharmacology Specialty Laboratory (Omaha, Nebraska, United States, October, 2017).

| Statistical test | p-value | Pearson correlation | Statistical measure of difference | Additional information |
|------------------|---------|---------------------|----------------------------------|-----------------------|
| Omnibus 2 for normality | < 0.0001* | - | K2 = 37.96 | Normal nevirapine steady state range: 5086 ng/mL – 13 368 ng/mL |
| (D'Agostino-Pearson) | < 0.0001* | - | K2 = 7.072 | UZ-IPSL assay range: 500 ng/mL – 15 000 ng/mL |
| All data points (n = 95) | < 0.0001* | - | K2 = 5.923 | |
| Data points ≤ 20 000 ng/mL (n = 92) | 0.0544 | - | - | |
| Data points ≤ 15 000 ng/mL (n = 88) | - | - | - | |
| Grubbs outlier test | < 0.05* | - | - | |
| Paired t-test | < 0.0001* | - | Mean of differences (UZ-IPSL – UNMC-PSL) = 95% confidence = 224.6–635.6 |
| Deming regression | < 0.0001* | - | UZ-IPSL = (1.155* UNMC-PSL) – 718.7 | 95% confidence slope from 1.077 to 1.234 |
| Bland-Altman, difference | < 0.0001* | R = –0.4278 95% confidence = –0.5856–0.2386 | UNMC-PSL = (–0.141* UNMC-PSL) + 683 | |
| Bland-Altman, % difference | 0.07246 | R = –0.2692 95% confidence = –0.4541–0.06205 | UNMC-PSL = (–0.007 UNMC-PSL) + 3.48 | |

**Source:** Clinical Pharmacology Quality Assurance, Proficiency Testing Unit. 2019. Blind nevirapine comparison report [not published]

**UZ-IPSL:** University of Zimbabwe International HIV Pharmacology Specialty Laboratory; UNMC-PSL, University of Nebraska Medical Center Pharmacology Specialty Laboratory.

*Statistically significant.
†One data pair in this range was identified as a significant outlier and was excluded from the final analysis.

**FIGURE 1:** Differences in nevirapine concentrations assayed at UNMC-PSL (Omaha, Nebraska, United States, October 2017) and UZ-IPSL (Harare, Zimbabwe, May 2018). (a) Scatter plot (n = 95 data points). (b) Deming regression plot of 87 data points (outliers excluded). Boxes in (a) indicate UNMC upper limit of quantitation (dashed) and UZ-IPSL upper limit of quantitation (solid lines).

UZ-IPSL, University of Zimbabwe International HIV Pharmacology Specialty Laboratory; UNMC-PSL, University of Nebraska Medical Center Pharmacology Specialty Laboratory.

The increasing proportional difference between the clinical pharmacology laboratories as the concentration of nevirapine increased. However, when the data were normalised by concentration, using the % difference analysis (Figure 2b), the correlation was no longer significant.

**Discussion**

Drug concentrations for nevirapine reported in the literature for HIV-positive individuals indicate a steady state maximum of 5740 ng/mL (5000–7440) and minimum of 3730 ng/mL (3200–5080)\(^\text{a}\). Both nevirapine assays from the two laboratories can detect concentrations that might be below the target concentration for virologic suppression or above the upper limit of the therapeutic range. Although the UZ-IPSL nevirapine concentrations were higher than those of UNMC-PSL and this difference was statistically significant, it is unlikely to have clinical significance. The
United States Food and Drug Administration does not provide a window of acceptance for cross-validation studies but allows laboratories to determine a priori the acceptance criteria. Using the established acceptance window for Clinical Pharmacology Quality Assurance PT samples, about 20% of the final target value, and expected concentrations of nevirapine, this difference was acceptable.

The outcomes of the cross-validation also presented an opportunity to perform a root-cause analysis. The UZ-IPSL’s trend of PT outcomes before and during the A5279 sample analysis period was explored. While all PT results were satisfactory, agreement of initial PT sample analyses showed unbiased accuracy, while during subsequent analyses which coincided with A5279 sample analysis, the UZ-IPSL values exhibited a biased, high trend (4% – 19%) as compared to the final target values of that PT round. This shift in bias and accuracy was provided within the PT report and the UZ-IPSL was able to complete a root-cause analysis and remediate as needed.

**Limitations**

One limitation to consider is that the calibration ranges for the two equipment sets used for the nevirapine analysis were not identical. Future comparisons of this nature may benefit from evaluations where the calibration range is the same for both laboratories. In addition, limited data points above 20 000 ng/mL entailed difficulties in quantitation of proportional error at that level.

**Conclusion**

The cross-validation study provided evidence that the UZ-IPSL performance using a nevirapine assay that was validated in their laboratory was acceptable and correlated with the results of an experienced PSL. This study afforded the UZ-IPSL a valuable opportunity to implement operations using its validated nevirapine assay for the analysis of samples obtained from a clinical research protocol and adopt procedures for handling of protocol specimens based on experience. Furthermore, the outcomes of the cross-validation emphasised the value of PT and provided an occasion to perform root-cause analysis.

**Acknowledgements**

The UZ-IPSL acknowledges the contribution of Dr Marshall Munjoma for his support during the laboratory work that led to the development of this manuscript.

**Competing interests**

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

**Authors’ contributions**

F.M.-C. was the project leader and F.M. was the laboratory technologist. T.Mudzviti and C.C.M. provided manuscript review and supervised the UZ-IPSL activities for the project. A.T.F. was clinical pharmacologist and C.V.F. was the PSL director and A5279 pharmacology investigator. T.Mykris and L.C.W. were laboratory technologists. A.J.O., R.W.B., R.D. and G.D.M. provided clinical pharmacology quality assurance project design and data analysis. All authors critically revised intellectual content and approved the final version to be published.

**Sources of support**

University of Zimbabwe IPSL: Project was funded by the United States National Institute of Allergy and Infectious Diseases, National Institutes of Health (AIDS Clinical Trials Group Grant SUM1AI106701-04).

University of Nebraska PSL: Project was funded by the United States National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services Awards ATP (K23 AI134307), and CVF (UM AI106701).

Clinical Pharmacology Quality Assurance Program: This project has been funded in whole or in part with federal funds from the United States National Institute of Allergy and Infectious Diseases, National Institutes of Health and the Department of Health and Human Services, under contract numbers HHSN272201500006C and HHSN272200800019C.

Center for AIDS Research: This publication was made possible through core services and support from the University of Rochester Center for AIDS Research, a United States National Institutes of Health-funded programme (P30 AI078498).

**Data availability**

Data are available from (1) Clinical Pharmacolog Quality Assurance Program Translational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, United States, (2) International PSL, School of Pharmacy, University of Zimbabwe College of Health Sciences, PO Box A178, Avondale, Harare, Zimbabwe and (3) Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, United States.

**Disclaimer**

The content is solely the responsibility of the authors and does not necessarily represent the official views of the United States National Institutes of Health.

**References**

1. Mtisi TJ, Maponga C, Monera-Penduka TG, et al. Strategic establishment of an International Pharmacology Specialty Laboratory in a resource-limited setting. Afr J Lab Med. 2018;7(1):a659. https://doi.org/10.4102/ajlm.v7i1.659
2. Makita-Chingombe F, Ocque AJ, DiFrancesco R, et al. Development and validation of a high performance liquid chromatography method to determine nevirapine in plasma in a resource-limited setting. Afr J Lab Med. 2019;8(1):a880. https://doi.org/10.4102/ajlm.v8i1.880

3. Bolaris MA, Keller MA, Robbins BL, Podany AT, Fletcher CV. Nevirapine plasma concentrations in human immunodeficiency virus-exposed neonates receiving high-dose nevirapine prophylaxis as part of 3-drug regimen. J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):102–104. https://doi.org/10.1093/jpids/piv084

4. Pav JW, Rowland LS, Korpalski DJ. HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. J Pharm Biomed Anal. 1999;20(1–2):91–98. https://doi.org/10.1016/S0731-7085(98)00312-4

5. Fan-Havard P, Liu Z, Chou M, et al. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Antimicrob Agents Chemother. 2013 May;57(5):2154–2160. https://doi.org/10.1128/AAC.02294-12

6. Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001–1011. https://doi.org/10.1056/NEJMoa1806808

7. United States Food and Drug Administration. Guidance for industry: Bioanalytical method validation. Rockville, MD: FDA; 2001.

8. Nevirapine PK fact sheet [homepage on the Internet]. 2016 [cited 2020 Mar 19]. https://liverpool-hiv-hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/059/original/HIV_FactSheet_NVP_2016_Mar.pdf?1520612265

9. Clinical Pharmacology Quality Assurance, Proficiency Testing Unit. 2019. Blind nevirapine comparison report [not published].